Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.

Bioorganic & medicinal chemistry letters - 15 Dec 2006

Nudelman Igor, Rebibo-Sabbah Annie, Shallom-Shezifi Dalia, Hainrichson Mariana, Stahl Ido, Ben-Yosef Tamar, Baasov Timor

Abstract excerpt

A series of new derivatives of the clinically used aminoglycoside antibiotic paromomycin were designed, synthesized, and their ability to read-through premature stop codon mutations was examined in both in vitro translation system and ex vivo mammalian cultured cells. One of these structures, a p...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to Carbohydrate Conformation
Share to Codon, Terminator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Genetic Diseases, Inborn

Share to Models, Molecular

Share to Molecular Conformation

Share to Mutation

Source

Identifiers

PMID: 16997553
DOI: 10.1016/j.bmcl.2006.09.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16997553-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations.PMID 16997553Read ↗

Aminoglycosides redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases.Semantic proximity Read ↗

Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsSemantic proximity Read ↗

Small molecule Y-320 stimulates ribosome biogenesis, protein synthesis, and aminoglycoside-induced premature termination codon readthrough.Semantic proximity Read ↗

Effects of gentamicin inducing readthrough premature stop Codons: A study of alpha-L-iduronidase nonsense variants in COS-7 Cells.Semantic proximity Read ↗

Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutationsSemantic proximity Read ↗

Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).Semantic proximity Read ↗

Effect of Readthrough Treatment in Fibroblasts of Patients Affected by Lysosomal Diseases Caused by Premature Termination Codons.Semantic proximity Read ↗

Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3′ UTRSemantic proximity Read ↗

Glycodiversification of gentamicins through <i>in vivo</i> glycosyltransferase swapping enabled the creation of novel hybrid aminoglycoside antibiotics with potent activity and low ototoxicitySemantic proximity Read ↗

Suppression of nonsense mutations by small, cyclic peptidesSemantic proximity Read ↗

Frontotemporal dementia non-sense mutation of progranulin rescued by aminoglycosidesSemantic proximity Read ↗

Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.